J&J's Spravato Set For EU Launches Soon
Ketamine-Like Antidepressant Backed By CHMP
If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
